ProfileGDS5678 / 1438225_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 37% 40% 39% 37% 34% 34% 35% 36% 37% 37% 54% 46% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8300835
GSM967853U87-EV human glioblastoma xenograft - Control 22.843837
GSM967854U87-EV human glioblastoma xenograft - Control 32.9195940
GSM967855U87-EV human glioblastoma xenograft - Control 42.827839
GSM967856U87-EV human glioblastoma xenograft - Control 52.7948837
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8511234
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8387334
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7922435
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.802336
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8382137
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.836537
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3025554
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0793546
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8478237